Interferons (IFNs) are a family of cytokines which have important antiviral and antiproliferative properties. They also play an important role in immunomodulation. Type I IFNs have been implicated in autoimmune diseases, including systemic lupus…
ID
Bron
Verkorte titel
Aandoening
Systemic Lupus Erythematosus, SLE
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary goal is to investigate the possibility of generating fully human monoclonal antibodies against type I interferons (IFNs) from B cells of SLE patients.
Achtergrond van het onderzoek
Blood will be collected from patients with a diagnosis of SLE. The initial study is aimed at generating fully human monoclonal antibodies against type I IFNs from B cells of SLE patients. For this purpose, 50 mL blood from three SLE patients, whose serum contains autoantibodies against type I IFNs, is required.
Doel van het onderzoek
Interferons (IFNs) are a family of cytokines which have important antiviral and antiproliferative properties. They also play an important role in immunomodulation. Type I IFNs have been implicated in autoimmune diseases, including systemic lupus erythematosus (SLE), where progressive loss of tolerance to nuclear antigens leads to a heterogenous, multisystem disease course characterized by flares and remissions.
The natural occurrence of autoantibodies against type I IFNs has already been described in the early 1980s in patients with SLE, acute viral infections, and malignancies. These findings imply the presence and activation of B cells, which are specific for the indicated cytokine, and it is possible that monoclonal anti-IFN antibodies derived from B cells of SLE patients have clinical value.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
No intervention, observational study with invasive measurements.
Publiek
P.O. Box 22660
P.P. Tak
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5662171
p.p.tak@amc.nl
Wetenschappelijk
P.O. Box 22660
P.P. Tak
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5662171
p.p.tak@amc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Male and female patients with a diagnosis of SLE and whose serum contains autoantibodies against type I IFNs.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Use of or history of use of B cell-directed therapies;
2. Pregnancy.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL2772 |
| NTR-old | NTR2912 |
| Ander register | METC AMC : 2011-085 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |